Table 2.
Changes in manometric characteristics (acotiamide; n = 16, placebo; n = 10)
| Baseline | Post-treatment | p value | ||
|---|---|---|---|---|
| LES pressure (median; mmHg) | Acotiamide | 10.7 (0.7–46.7) | 16.0 (0–48.4) | 0.410 |
| Placebo | 16.1 (0.6–38.2) | 17.8 (3.8–27) | 0.332 | |
| IRP4s (mmHg) | Acotiamide | 8.9 (0–27.4) | 10.9 (0–29.6) | 0.023 |
| Placebo | 11.5 (3.5–26.8) | 12.9 (3.7–17) | 0.414 | |
| Peristaltic break (cm) | Acotiamide | 3.1 (0–16.1) | 0.8 (0–17) | 0.020 |
| Placebo | 0.1 (0–4.1) | 0.2 (0–14.1) | 0.362 | |
| DCI (mmHg cm s) | Acotiamide | 1500.1 (349.1–8935.9) | 3036.1 (238.2–9174.1) | 0.410 |
| Placebo | 3858.1 (961.7–8158.7) | 3693.5 (953.4–10,118.1) | 0.759 | |
| CFV (cm/s) | Acotiamide | 3.2 (2.5–26.9) | 4.1 (0–8.39 | 0.162 |
| Placebo | 3.1 (2.3–5.1) | 3.5 (1.8–6.1) | 0.358 | |
| % Success peristalsis | Acotiamide | 100 (0–100) | 100 (0–100) | 0.199 |
| Placebo | 100 (40–100) | 100 (20–100) | 0.845 |
Data were expressed as median (interquartile range)
LES lower esophageal sphincter, IRP integrated relaxation pressure, DCI distal contractile integral, CFV contractile front velocity